Comparing Meniscal Repair Biologic Augmentation: Marrow Venting Procedure Versus PRP (MVP Trial)

Meniscal Tear Clinical Trial

Official title:

Comparing Meniscal Repair Biologic Augmentation: Marrow Venting Procedure Versus PRP (MVP Trial)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04775004
• Other study ID #: IRB20-1394
• Status: Recruiting
• Phase: N/A
• Start date: July 19, 2021
• Est. completion date: March 2024

Study information

• Verified date: July 2022
• Source: University of Chicago
• Contact: Justin Bell
• Phone: 773-834-0822
• Email: jbell3[@]bsd.uchicago.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There are no current or past RCT comparing biologic augments for meniscal repair. There is good data supporting both the use of BMVP of the intercondylar notch and intra-articular PRP injections for augmentation of meniscal repair. However, the effectiveness of these augmentation methods with respect to each other has never been investigated. The knowledge gained will allow us to potentially influence and adapt protocols to treat this particular patient population. Additionally, resources available at our institution provide a supportive framework with which to maintain contact with patients after hospital discharge. These key factors will allow us to perform a robust analysis of this population, to include outcomes measures of function as well as meniscal repair failure and reoperation rate.

The proposed interventional aim to compare meniscal repair augmentation methods is novel, as the direct comparison of these outcome measures has not been previously described. Because of the known benefit of biologic augmentation of meniscal repair, the investigators hypothesize that the repair failure rate for both cohorts will be lower than the reported repair failure rate for isolated tears without biologic augmentation; the investigators also hypothesize that BMVP of the intercondylar notch will clinically be significantly better than intra-articular PRP injection. The basis behind this hypothesis is in vivo evidence as well as a small RCT supporting the use of BMVP as augmentation for meniscal repair procedures.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 146
• Est. completion date: March 2024
• Est. primary completion date: March 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria

1. Age 16 or older

2. Medial, lateral, vertical longitudinal, oblique, or radial meniscal tear

3. Complex tears may be included at the discretion of the site investigator if patient has one of tear patterns listed in inclusion criteria 2 as the most predominant finding

4. No other concomitant procedure unless one of the following:

• Chondroplasty

• Synovectomy

• Loose body removal

• "Contralateral" menisectomy (i.e. medial meniscus repair with a lateral menisectomy or lateral meniscus repair with a medial menisectomy) would be permitted for inclusion

• Any other procedure that does not include drilling, requires prior approval of the study sponsor for each procedure

Exclusion Criteria

1. Patients requiring cartilage restorative or repair procedures (i.e. OCD fixation, micro-fracture repair, or others)

2. Patients with meniscus root tears

3. Patients undergoing repair for horizontal cleavage tears

4. Kellgren-Lawrence scale 3>

5. Patients undergoing lateral release

6. Ipsilateral chondral lesion with Outerbridge classification of 3-4

7. Use of prednisone or other steroids, any immunosuppressant, or chemotherapy 1-week before surgery or expected use within six weeks after surgery

8. Cortisone use within the six weeks prior to surgery

9. Utilizing worker's compensation at the time of screening

10. Any previous ligament surgery on the index limb. Any previous meniscal surgery on the index meniscus.

11. Concomitant ligamentous insufficiency

12. Inflammatory rheumatic disease or other rheumatic disease

13. Immune compromised patients (hepatitis, HIV, etc.)

14. Any nicotine based products within the three months prior to surgery (including cigarettes, cigars, vaping, nicotaine patch, etc)

15. History of distal femur, proximal tibia, or patellar fracture that was treated operatively

16. Non English-speaking patients

Related Conditions & MeSH terms

• Meniscal Tear

Intervention

Other:
• Bone marrow venting procedure (BMVP)
The BMVP involves creating small holes in a non-weight bearing area of the bone that does not have any important structures; the holes act as channels, which allow for flow of the participants own biologic products and stem cells from within the bone marrow.
• Platelet Rich Plasma (PRP)
The PRP group will have 40cc to 60cc (about 3 tablespoons) of blood drawn at the time of surgery. The blood sample will then be prepared in a centrifuge machine to collect a component of the blood called platelet rich plasma. Once appropriate concentrations of the PRP are confirmed, the PRP will be injected into the subject's knee prior to wound closure.

Locations

Country	Name	City	State
United States	University of Chicago Medicine	Chicago	Illinois
United States	University of Florida	Gainesville	Florida
United States	Wake Forest University Health Sciences	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
University of Chicago	American Orthopaedic Society for Sports Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Promis Physical function CAT lower extremity score	Adaptive questionnaire that takes five minutes or less to complete and helps record how subject injury and recovery from surgery is affecting their normal life.	1-year after meniscus tear operation.
Secondary	Re-tear of repair meniscus	Clinically reported (symptomatic) and MRI confirmed via observation of fluid filled tear in the repaired tissue	1-year after meniscus tear operation.